Tango Therapeutics

United States · 140 Employees
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

概述

国家 United States
成立时间 2017
总部 100 binney st, boston, massachusetts, united states
电话号码 +1 857-320-4900
网站 http://www.tangotx.com
LinkedIn http://www.linkedin.com/company/tango-therapeutics
Twitter
Facebook
员工数 140
行业 research,
简介 Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

技术

Akamai RUM

Web Performance Monitoring

Atlassian Cloud

CMS

EasyDNS

Domain Name Services

Google Cloud Hosting

Hosting

Google Font API

Fonts

Google Tag Manager

Tag Management

Greenhouse.io

Recruitment

Microsoft Office 365

Other

Mimecast

Email Providers

Mobile Friendly

Other

New Relic

Web Performance Monitoring

Nginx

Load Balancers

Outlook

Email Providers

Remote

Other

Render

Other

Vimeo

Online Video Platforms

WP Engine

CMS

WordPress.org

CMS

Zendesk

Support and Feedback

常见问题

Tango Therapeutics 在哪里?

Tango Therapeutics 的总部位于 100 binney st, boston, massachusetts, united states

Tango Therapeutics 的电话号码是多少?

Tango Therapeutics 的电话号码是 +1 857-320-4900

Tango Therapeutics 的官方网站是什么?

Tango Therapeutics 的公司官方网站是 http://www.tangotx.com

Tango Therapeutics 是做什么的?

Tango Therapeutics 的业务有哪些?

cancer,pharmaceutical research,functional genomics,drug discovery,synthetic lethality

Tango Therapeutics 的年收入是多少?

Tango Therapeutics 的收入是 24868000美元

Tango Therapeutics 有多少员工?

Tango Therapeutics 有 140 名员工

Tango Therapeutics 属于哪个行业?

Tango Therapeutics 从事以下行业: research

Tango Therapeutics 使用什么技术?

Tango Therapeutics 使用的一些流行技术包括: Akamai RUM,Atlassian Cloud,EasyDNS,Google Cloud Hosting,Google Font API,Google Tag Manager,Greenhouse.io,Microsoft Office 365,Mimecast,Mobile Friendly,New Relic,Nginx,Outlook,Remote,Render,Vimeo,WP Engine,WordPress.org,Zendesk

如何联系 Tango Therapeutics?

Tango Therapeutics 联系信息: 电话号码:+1 857-320-4900, 网站:http://www.tangotx.com, 邮箱:bsh***@***.com

Tango Therapeutics 的社交媒体链接是什么?

Tango Therapeutics 领英:http://www.linkedin.com/company/tango-therapeutics,fackbook:,twitte:

Tango Therapeutics 是一家上市公司吗?

是的,Tango Therapeutics是一家上市公司,在nasdaq公开挂牌上市,上市交易代码:TNGX

Tango Therapeutics 的最后一轮融资是什么时候?

暂无最近投资信息

谁投资 Tango Therapeutics?

Tango Therapeutics 有 0 家投资者,包括 。

管理层

Binzhang Shen

Senior Principal Scientist

Colin Liang

Director, Process Chemistry, CMC

Amanda Galgay

Senior Vice President Communications

Jon Come

Senior Director

Jade Green

Manager, Administration

员工

Doug Barry

General Counsel and Chief Compliance Officer

Ron W

Former Chief Medical Officer

Frank Bruzzese

Principal Scientist

Nikitha Das

Associate Scientist

外贸获客 查找关键决策人

10亿+海关交易数据,1.2亿企业数据,2亿+企业联系人数据,1000千万真实采购商。覆盖200+个国家及地区,95%外贸重点拓展市场,可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少,成就更大,销售更聪明

查找更多 B2B 联系人,丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google